592 results on '"Nukiwa, T"'
Search Results
2. Mycobacterium avium genotype is associated with the therapeutic response to lung infection
3. Nationwide prospective registry of idiopathic interstitial pneumonias with central multidisciplinary diagnosis in Japan (JIPS Registry): Analysis of disease progression
4. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
5. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer
6. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405
7. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells
8. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival
9. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000
10. The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes
11. THE PHARMACOKINETICS OF BIBF 1120 ALONE OR IN COMBINATION WITH PIRFENIDONE IN JAPANESE PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): 799
12. Pirfenidone Delays the Prescription of Concomitant Drugs in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Japanese Phase III Clinical Trial
13. Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection
14. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis
15. Papillary adenoma of type II pneumocytes might have malignant potential
16. O1–137 - PHASEII Study of S-1 with Irinotecan Combination Therapy for EGFR-Mutated NSCLC Resistant to EGFR-TKI: NJLCG0804
17. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis
18. IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients
19. Bilateral pneumothoraces with multiple bullae in a patient with asymptomatic bronchiolitis obliterans 10 years after bone marrow transplantation
20. Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals
21. Towards an Effective Gene Therapy for Idiopathic Pulmonary Fibrosis*: Anti-inflammation, Antifibrosis, and Regeneration
22. Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma
23. Effect of Hepatocyte Growth Factor on Lung Injury and Development of Clinical Application*
24. P2.14-52 The Results from Plasma EGFR Mutation Analysis in NEJ026 Study
25. Follow-up of patients with superior vena cava syndrome by functional analysis of radionuclide venography
26. Hepatocyte growth factor in bronchoalveolar lavage fluids and cells in patients with inflammatory chest diseases of the lower respiratory tract: detection by RIA and in situ hybridization.
27. Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan.
28. Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung.
29. Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
30. A phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027
31. Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
32. P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
33. P2.03-010 Updated Survival Outcomes of NEJ005/TCOG0902, a Randomized PII of Gefitinib and Chemotherapy in EGFR-Mutant NSCLC
34. P2.03-021 A Phase I Study Evaluating the Combination of Afatinib, Carboplatin and Pemetrexed after Failure of 1st Generation EGFR-TKIs
35. P3.01-035 Post-Marketing Observational Study of Japanese Patients with EGFR Mutation-Positive (EGFRm+) NSCLC Treated with Daily Afatinib (Final Report)
36. NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
37. 1445P - A phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027
38. 1441P - Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
39. 1382PD - Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
40. 3067 Randomized phase II trial of standard daily administration versus alternate-day administration of S-1 in patients with advanced non-small cell lung cancer: North Japan Lung Cancer Group Trial NJLCG1102
41. Final Result of Randomized Phase 2 Trial Comparing Amrubicin (A) with Re-Challenge of Platinum Doublet (P) in Patients (Pts) with Sensitive-Relapsed Small-Cell Lung Cancer (Sclc): Njlcg0702
42. Randomized Phase Ii Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer (Nsclc) with Sensitive Egfr Mutations: Nej005/Tcog0902
43. Final Results of a Randomized Phase 2 Study Comparing Carboplatin Plus Irinotecan (Ci) Versus Carboplatin Plus Amrubicin (Ca) for Extensive Disease Small-Cell Lung Cancer: Njlcg0901
44. [Non-small-cell lung cancer (NSCLC) in an elderly patient--a case of squamous cell carcinoma successfully treated with chemotherapy using vinorelbine]
45. [Assessment of noninvasive therapy in lung cancer using lung perfusion images]
46. 1286TiP - NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
47. Secretory leukocyte protease inhibitor modulates urethane-induced lung carcinogenesis
48. PHASEII Study of S-1 with Irinotecan Combination Therapy for EGFR-Mutated NSCLC Resistant to EGFR-TKI: NJLCG0804
49. Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma
50. Prognostic Factors in Non-Small-Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations: Data from the Randomized Phase III Study Compared Gefitinib with Carboplatin Plus Paclitaxel (NEJ002)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.